德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs 2023-11-08 08:30
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting 2023-11-01 08:30
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting 2023-09-28 08:30
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 2023-09-21 18:05
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline 2023-08-25 19:37
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China 2023-08-11 08:00
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States 2023-07-18 08:30
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2023-07-17 08:30
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2023-06-01 10:09
Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023 2023-05-26 09:41
Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers 2023-05-23 17:25
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 2023-05-18 11:53
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 2023-05-18 02:47
Antengene Announces NDA Submission for XPOVIO® in Indonesia 2023-05-17 08:30
Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO 2023-04-27 08:30
Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting 2023-04-17 20:22
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia 2023-03-29 08:30
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation 2023-03-28 21:40
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting 2023-03-20 15:20
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China 2023-03-14 12:29
1 2 3 4 5 9